Mallinckrodt spinning off next year If the drops aren't doing it for you then take a pill. Mallinckrodt using the same sales force for Pennsaid for the new pill. Pop or drip? I say Pop or gel. Forget the drip. Need2.
Published: June 18, 2012
Mallinckrodt Announces Co-Promotion Arrangement for DUEXIS®
Under the terms of the agreement, Mallinckrodt's U.S. sales force will sell DUEXIS through December 31, 2014. Horizon and Mallinckrodt have agreed upon physician promotion targets and Mallinckrodt will be compensated for each prescription generated from these targets. The Mallinckrodt sales force is expected to begin promoting DUEXIS to physicians in August 2012. Horizon will continue to record all revenues and remain responsible for DUEXIS manufacturing, supply and regulatory activities.
"This agreement represents a key component of our growing pharmaceuticals business as Mallinckrodt prepares to spin off from Covidien next year," said Mark Trudeau, President, Pharmaceuticals. "We are leaders in pain management, and adding DUEXIS to our portfolio will further advance our efforts to help patients manage the often-debilitating impact of pain. We look forward to working with Horizon and providing DUEXIS to our customers."
"The addition of Mallinckrodt's experienced sales force will expand our reach and frequency into the osteoarthritis and rheumatology markets," said Timothy P. Walbert, Chairman, President and Chief Executive Officer, Horizon Pharma.
Mallinckrodt is the largest U.S. supplier of opioid pain medications and among the top 10 generic pharmaceuticals manufacturers in the U.S., based on prescriptions. Its branded portfolio includes EXALGO (hydromorphone HCl) Extended-Release Tablets (CII) and PENNSAID (diclofenac sodium topical solution) 1.5% w/w. Mallinckrodt is also one of the world's leading producers of bulk acetaminophen.
Covidien announced last December that the Company planned to spin off Mallinckrodt into a stand-alone company, a process that is expected to be completed in mid-2013.